Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients.
Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.
Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
Definition of the viral targets of protective HIV-1-specific T cell responses.
Human papillomavirus genotype distribution and human papillomavirus 16 and human papillomavirus 18 genomic integration in invasive and in situ cervical carcinoma in human immunodeficiency virus-infected women.
Deep molecular characterization of HIV-1 dynamics under suppressive HAART.
Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
Plasma and intracellular (peripheral blood mononuclear cells) pharmacokinetics of once-daily raltegravir (800 milligrams) in HIV-infected patients.